Tuberculosis and neurocryptococcosis by Cryptococcus neoformans molecular type VNI in A non-HIV patient: A comorbidities case report.

J Mycol Med

Post-Graduation Program in Biology of Fungi, Department de Mycology, Federal University of Pernambuco (UFPE), Recife, Pernambuco, Brazil; Department of Tropical Medicine, UFPE, Recife, Pernambuco, Brazil. Electronic address:

Published: March 2022

Mycobacterium tuberculosis, which is responsible for tuberculosis (TB) and Cryptococcus sp. responsible for cryptococcosis, are pathogenic microorganisms that especially affect patients infected with the human immunodeficiency virus (HIV). Both diseases present similar classic symptoms, which makes diagnosis and treatment consequently difficult. To our knowledge, a few reported cases of M. tuberculosis and Cryptococcus sp. co-infection in non-HIV patients exist. This study reports a TB and neurocryptococcosis (NC) comorbidity case in a patient who had no clinical or serological evidence of HIV-compromised immunity. A 49-year-old male patient, a farmer with a low education level, previously diagnosed with TB and was undergoing treatment for a month when he presented progressive headaches, fever, drowsiness and photosensitivity, a stiff neck and a positive Lasègue test. During hospitalization, the patient was also diagnosed with NC through cerebrospinal fluid (CSF) analysis, which revealed the presence of capsulated yeasts by contrast with india ink. Following the yeast isolation, proteomic and molecular analyzes were performed. The patient received antifungal therapy in parallel with TB treatment, which caused complications and had to be modified twice. However, after three months of hospitalization the patient was discharged. Tuberculosis and cryptococcosis co-infection is a clinical and laboratory challenge, often leading to a delay in diagnosis. In this paper we emphasize the need to understand these infectious comorbidities in non-HIV patients from South America, since the few cases reported in the literature are from studies conducted in the United States and China.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mycmed.2021.101213DOI Listing

Publication Analysis

Top Keywords

tuberculosis cryptococcus
8
non-hiv patients
8
hospitalization patient
8
patient
6
tuberculosis
5
tuberculosis neurocryptococcosis
4
neurocryptococcosis cryptococcus
4
cryptococcus neoformans
4
neoformans molecular
4
molecular type
4

Similar Publications

is a fungal pathogen that can cause lethal disease in immunocompromised patients. Immunocompetent host immune responses, such as formation of pulmonary granulomas, control the infection and prevent disseminated disease. Little is known about the immunological conditions establishing the latent infection granuloma in the lungs.

View Article and Find Full Text PDF

IL-22 and IL-23 regulate the anticryptococcal response during infection.

iScience

October 2024

Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-900, Brazil.

Article Synopsis
  • Cryptococcosis, caused by environmental fungi, leads to severe pneumonia and systemic infections, especially in immune-compromised individuals, with rising cases seen in immunocompetent hosts due to strain R265.* -
  • The study investigates the roles of cytokines IL-22 and IL-23 in managing lung health during R265 infections, revealing their importance in preserving lung barrier integrity and preventing excessive damage.* -
  • Findings indicate that IL-22 helps control neutrophil activity and promotes eosinophil presence in the lungs, providing crucial insights into immune response and tissue management during aggressive cryptococcal infections.*
View Article and Find Full Text PDF

Patterns of Amphotericin B Use and Factors Related to Mortality in a Low-Middle Income Country: An Observational and Longitudinal Study.

Antibiotics (Basel)

October 2024

Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira-Audifarma S.A., Pereira 660003, Colombia.

Article Synopsis
  • Amphotericin B is primarily used to treat deep systemic fungal infections, with a study analyzing its effects on Colombian patients from 2015 to 2022.
  • The study found that 40.3% of the 310 patients died during hospitalization, with factors such as higher comorbidity and the need for invasive procedures significantly increasing mortality rates.
  • The research highlighted that while conventional amphotericin B was the main treatment, receiving systemic corticosteroids was associated with a lower risk of death.
View Article and Find Full Text PDF
Article Synopsis
  • A 3-year-old boy undergoing treatment for disseminated tuberculosis developed scalp swelling, prompting a needle aspirate.
  • The aspirate identified yeasts inside macrophages, initially misdiagnosed as Histoplasmosis but later confirmed as Cryptococcosis.
  • Treatment with liposomal amphotericin B and fluconazole led to the resolution of lesions, marking this as a rare pediatric case of cryptococcosis from Odisha.
View Article and Find Full Text PDF
Article Synopsis
  • * The patient was treated with a combination of antibiotics and antifungal medications over a month, including isoniazid, rifampicin, ethambutol, and liposomal amphotericin B, showing symptom improvement.
  • * The case emphasizes the importance of using microscopy, culture, and rapid molecular diagnostics for early detection and treatment of infectious meningitis.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!